Although there are many studies focusing on the molecular pathways underlying lung vascular morphogenesis, the extracellular matrix (ECM)-dependent regulation of mesenchymal cell differentiation in vascular smooth muscle development needs better understanding. In this study, we demonstrate that the paired related homeobox gene transcription factor Prx1 maintains the elastic ECM properties, which are essential for vascular smooth muscle precursor cell differentiation. We have found that Prx1 null mouse lungs exhibit defective vascular smooth muscle development, downregulated elastic ECM expression, and compromised transforming growth factor (TGF)-β localization and signaling. Further characterization of ECM properties using decellularized lung ECM scaffolds derived from Prx1 mice demonstrated that Prx1 is required to maintain lung ECM stiffness. The results of cell culture using stiffness-controlled 2-D and 3-D synthetic substrates confirmed that Prx1-dependent ECM stiffness is essential for promotion of smooth muscle precursor differentiation for effective TGF-β stimulation. Supporting these results, both decellularized Prx1 null lung ECM and Prx1 WT (wild type) ECM scaffolds with blocked TGF-β failed to support mesenchymal cell to 3-D smooth muscle cell differentiation. These results suggest a novel ECMdependent regulatory pathway of lung vascular development wherein Prx1 regulates lung vascular smooth muscle precursor development by coordinating the ECM biophysical and biochemical properties.
Proper vascular morphogenesis is critical for the development and regeneration of functional lung tissue and is required for the lungs' main function of oxygenation. Recently, studies in stem cell differentiation exploring new pathways to morphogenesis have shown more dynamic interactions between microenvironmental cues and cells in this process. However, while intense research has been performed focusing on molecular networks regulating vascular morphogenesis, the mechanisms underlying extracellular matrix (ECM)dependent vascular cell differentiation are not well understood.
The ECM is composed of a large collection of biochemically distinct components with different physical and biochemical properties. 1 When constructed in an orderly manner, the ECM components possess unique physical, biochemical, and biomechanical properties that are essential for regulating cell behavior beyond providing structural support.
Growing evidence demonstrates that specific biophysical properties of ECM stiffness play an essential role in guiding stem/progenitor cell differentiation. [2] [3] [4] [5] For instance, the differentiation of human mesenchymal stem cells into an osteogenic phenotype was shown to be dependent on ECM stiffness. 2, 4 In contrast, biochem-ical properties of the ECM pertaining to its indirect or direct signaling capabilities allow cells to respond to microenvironmental cues using various signaling cascades. For example, the ECM can bind to myriad growth factors, 6, 7 including transforming growth factor (TGF)-β, 8 and by doing so the ECM regulates growth factor distribution, activation, and presentation to cells in a spatially organized and regulated manner. 9 During embryonic lung development, the biochemical properties of the ECM is essential for lung morphogenesis, which requires temporal and spatial gradients of growth factors surrounding the developing airway and vessels. 8, 10 These findings indicate that the signals from the environment surrounding the developing tissue play a pivotal role in guiding stem/progenitor cell fate determination and differentiation, while the role played by the ECM in cell signaling has not yet been well explained.
In the lungs, elastin and its associated microfibrils (i.e., fibrillins) are the major components of the lung ECM, and they play a pivotal role in lung homeostasis. Elastic ECM not only provides structural support for lung tissue, 11, 12 it appears to play a regulatory role in smooth muscle cell (SMC) proliferation and differentiation. 13, 14 Defects in both elastin and fibrillins result in vascular SMC growth abnormalities in human disease and animal models. 8, [13] [14] [15] [16] Furthermore, TGF-β, a known regulator of stem/progenitor cell to vascular SMC differentiation, 17, 18 requires a level of ECM stiffness for latent form activation. 19, 20 In addition, fibrillin (Fbn) 1 modulates local TGF-β activation in the lungs by binding to the latent form of TGF-β. 8 While this evidence highlights the pivotal role played by the ECM in lung vascular progenitor cell differentiation and functional maturation, the mechanism whereby elastic ECM regulates embryonic vascular cell differentiation is obscure.
To elucidate the mechanisms of elastic ECM-dependent lung vascular smooth muscle development, we focused on the homeobox gene transcription factor Prx1. In humans, several reports have suggested that agnathia-otocephaly complex (AGOTC) could be caused by a heterozygous mutation in the PRRX1 gene (167420) on chromosome 1q24. [21] [22] [23] [24] AGOTC is a rare, often lethal malformation characterized by absence or hypoplasia of the mandible, microstomia, hypoglossia/aglossia, and variable anterior midline fusion of the ears (melotia, synotia) that exhibits many similarities to the hypoplastic features of Prx1 null homozygote mice, 25 which exhibit skeletal defects affecting mandible, limbs, and vertebrae as well as vascular abnormalities and neonatal lethality. In addition, it has been shown that Prx1 colocalized with fibrillins within the developing elastic vascular wall during embryonic development. 26, 27 This suggests a tight association between Prx1 and fibrillins during vascular development, as a fibrillin mutation leads to abnormal morphogenesis in Marfan syndrome. 28, 29 Taken together, these lines of evidence suggest that Prx1 may regulate the composition of the elastic ECM and thereby have an effect on vascular development. Therefore, we hypothesized that Prx1 controls lung vascular smooth muscle development through its effects on the properties of the ECM. To investigate this hypothesis, we characterized the biochemical and biophysical ECM properties of Prx1 WT (wild type) and Prx1 null lungs and examined the effects of Prx1-dependent ECM on lung vascular smooth muscle development. The outcome of this study should contribute greatly to a better understanding of ECMdependent embryonic lung tissue development and support the development of more effective therapies for tissue regeneration in pathological conditions of both newborns and adults.
METHODS

Animals
Prx1 gene knockout mice were generated as described elsewhere. 30 Polymerase chain reaction (PCR) was used to identify the three different expected genotypes: Prx1 WT (wild type), Prx1 heterozygous, and Prx1 null (homozygous-null). Genomic DNA from mouse tail was used in PCRs with the combination of primer pairs for the Prx1 WT allele and the Prx1 lacZ allele. All animal experiments were conducted in accordance with current National Institutes of Health (Bethesda, MD) guidelines.
Cell culture C3H10T1/2 (10T1/2) cells (ATCC) were used as mesenchymal SMC precursor cells. 17 Except in the case of TGF-β stimulation experiments, cells were maintained in 10% fetal bovine serum contain-ing Dulbecco's modified Eagle medium. Cells were cultured at 37°C in a humidified atmosphere with 5% CO 2 until used for cellular experiments.
Transient transfection
Cytomegalovirus plasmid containing Prx1 construct 30 and control vector were used to examine the downstream genes regulated by Prx1.
Decellularization of lungs
Intact fetal mouse lungs from E15.5 to D0 from Prx1 WT and Prx1 null mice were treated with hypotonic Tris buffer (pH 8) followed by hypertonic Tris buffer containing 1% Triton X-100 (pH 8). 31 After decellularization, lung scaffolds were processed for characterization or left unfixed for biomechanical testing. Intact lungs were used as controls for decellularization experiments.
Polyacrylamide (PAA) gels
PAA gels of variable stiffness were prepared on glass coverslips using an established method. 32 After being treated with sulfo-SANPAH (Thermo Fisher Scientific, Waltham, MA), collagen I (0.2 mg/mL; Advanced Biomatrix, Carlsbad, CA) was crosslinked to the gels before cells were plated.
Synthetic 3-D scaffolds (electrospun hyaluronic acid scaffolds)
Methacrylated hyaluronic acid (MeHA) was synthesized as described elsewhere. 33, 34 Briefly, MeHA was cospun with the carrier polymer PEO (molecular weight, 900 kDa; Sigma-Aldrich, St. Louis, MO) as described elsewhere, 34, 35 and fiber size and view morphology were quantified by scanning electron microscopy (SEM; 7500F HRSEM; Jeol, Glen Ellyn, IL). After polymerization was accomplished by exposing ∼10 mW/cm 2 365-nm light (Omnicure S1000 UV Spot Cure System; Exfo, Quebec City, QC), scaffolds were immersed in deionized H 2 O and washed to reach equilibrium swelling. The mechanical properties of MeHA gels were controlled by percent methacrylation or concentration of polymer used, and their stiffness was determined by atomic force microscopy (AFM).
Immunohistochemistry
The following primary antibodies were used: anti-Fbn1 and anti-Fbn2 antibodies (gift from R. Mecham, Washington University, St. Louis, MO), anti-tropoelastin antibody (Abcam, Cambridge, UK), anti-α-smooth muscle actin (SMA) antibody (Sigma-Aldrich), antiγ-SMA antibody (Santa Cruz Biotechnology, Dallas, TX), anti-SM22α antibody (Abcam), anti-smooth muscle myosin heavy chain (SMMHC) antibody (Abcam), anti-TGF-β1 antibody (Promega, Madison, WI), and anti-TGF-β2 antibody (R&D Systems, Minneapolis, MN). For staining controls, equivalent concentrations of isotypematched immunoglobulin (Ig) G were used. Sections were blocked for endogenous peroxidase activity, treated for antigen retrieval, and blocked for nonspecific antibody binding before being incubated with primary antibodies. The following dilutions were used for primary antibodies: Fbn1 and Fbn2 (1 ∶ 100), tropoelastin (1 ∶ 150), α-SMA (1 ∶ 400), γ-SMA (1 ∶ 50), SM22α (1 ∶ 100), and SMMHC (1 ∶ 100). Antigen detection was performed using species-specific secondary antibodies in conjunction with a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA), followed by the 3,3′diaminobenzidine reaction (Vector Laboratories), counterstaining with hematoxyline (Vector Laboratories), and processing for brightfield imaging (90i microscope; Nikon, Tokyo).
Immunofluorescence staining
Cells or scaffolds were fixed in 4% paraformaldehyde and then permeabilized with 0.2% Triton X-100-containing phosphate-buffered saline. Next, materials were treated with blocking buffer and incubated with the following primary antibodies. To examine SMC differentiation, antibodies specific for α-SMA, γ-SMA, SM22α, and SMMHC were used. For detection of ECM components, antibodies specific for Fbn1, Fbn2, tropoelastin, and TGF-β1 were used. Speciesspecific fluorescent-conjugated antibodies (Molecular Probes, Thermo Fisher Scientific) were used for antigen detection. Stained materials were examined using a 90i fluorescence microscope (Nikon) or a LSM 710 two-photon confocal microscope (Zeiss, Jena; CDB Imaging Core at the University of Pennsylvania, Philadelphia, PA).
Electron microscopy
Transmission electron microscopy (TEM). Intact or decellularized embryo lungs were processed for TEM using a modification of a protocol described elsewhere. 30 Ultrathin sections of Epon 812embedded (EMS, Hatfield, PA) specimens were stained with ulanyl acetate and lead citrate before being examined under a 1010 electron microscope (Jeol).
SEM. Lung materials were fixed, dehydrated, and then chemically dried using hexamethyldisilazane. Dried specimens were Palladium sputter coated before being examined under an XL20 ESEM (Philips, Amsterdam).
Western immunoblotting
Protein was extracted from lung tissue and concentrations were determined using the Pierce Protein Assay Reagent (Thermo Fisher Scientific). Ten micrograms of protein was separated on an 8%-16% Tris-HCl sodium dodecyl sulfate-PAA gel and then transferred to polyvinylidene fluoride membranes. After being incubated with blocking buffer, membranes were incubated with primary antibodies using the following: Fbn1 and Fbn2 (gift of R. Mecham), tropoelastin (Abcam), TGF-β1 (Promega), phosphorylated Smad2 (Cell Signaling Technology, Danvers, MA), and total Smad2/3 (Cell Signaling Technology). After incubation with species-specific secondary antibodies conjugated with horseradish peroxidase, protein was visualized using an enhanced chemiluminescence kit and examined using a Fuji imager (Fujifilm, Tokyo/GE Healthcare, Chalfont St Giles, UK). β-Actin (Sigma-Aldrich) was used as a loading control.
Real-time quantitative PCR
Total RNA was extracted from lung tissue or cells, and complementary DNA (cDNA) was then synthesized and processed for SYBR green-based real-time quantitative PCR analysis using the LightCycler 480 instrument (Roche, Basel). All target gene expressions were normalized to a housekeeping gene.
Stiffness measurements
Indentation testing. The stiffness of decellularized lung scaffolds was measured using a custom-made microindenter. 36 Briefly, lung scaffolds were brought into contact with the probe (bluntended tungsten wire, 550 μm in diameter), and the magnitudes of indentation and force were measured. The average indentation and force on the sample were derived and used to quantify sample stiffness by the method of Hayes et al. 37 Mechanical testing by AFM. To measure the stiffness of HA scaffolds at the tissue level, synthesized HA scaffolds were rehydrated, and the mechanical force was measured by AFM. The mechanical force was calculated using a cantilever spring constant determined by the vendor's thermal method.
TGF-β stimulation experiments
Cells were incubated with serum-free medium overnight before being treated with recombinant TGF-β1 (Cell Signaling Technology). 17 Either cells were fixed for immunostaining or total RNA was harvested for real-time PCR.
TGF-β function-blocking experiments
TGF-β blocking. Ten micrograms of neutralizing antibody per milliliter against TGF-β1 (R&D Systems) was added to the medium when 10T1/2 cells were seeded in the decellularized scaffolds. As a control, an identical concentration of chicken IgY (R&D Systems) was added to the medium. 10T1/2 cell differentiation was examined by immunostaining, and intensity was quantified using ImageJ software (National Institutes of Health).
TGF-βR1 signaling blocking. 10T1/2 cells were serum starved overnight before being incubated with 10 mM SB431542 (Cell Signaling Technology) or 10 mM LY364947 (Sigma-Aldrich) with or without TGF-β1 stimulation and then processed for immunostaining or real-time PCR to examine canonical TGF-β signaling pathways. As a control, vehicle alone was added to the medium.
Statistics
All experiments were performed in triplicate unless otherwise stated. Statistical analysis was performed using Prism software (GraphPad, San Diego, CA) to compare the groups. One-way analysis of variance with the Newman-Keuls posttest was used to compare more than two groups, and the unpaired Student t test was used to compare two groups. A P value of less than 0.05 was considered significant. All values are shown as means ± SD unless otherwise specified.
Detailed methods are available in the supplement.
RESULTS
Prx1 regulates expression of elastic ECM components during lung development
We first examined expression of elastic ECM components in Prx1 WT and Prx1 null lungs to determine whether Prx1 regulates ex-pression of the major elastic ECM components within developing lungs. We focused on E15.5 to newborn (D0) stages since the expression level of lung ECM components is higher during the late gestational period. The expression of tropoelastin, Fbn1, and Fbn2 was significantly lower in Prx1 null lungs than in Prx1 WT lungs at both the protein (Figs. 1A, 1B, S1; Figs. S1-S3 are available online) and the messenger RNA (mRNA; Fig. 1C ) level. Immunohistochemical studies also suggested that tropoelastin protein expression was significantly reduced around the developing vessels and in the adjacent mesenchyme (Fig. 1A , bottom) as well as around airways. Collectively, these data suggest that Prx1 controls the composition of the elastic ECM in developing lung vessels. To investigate further, we examined the ultrastructure of vessels in E17.5 embryo lungs using TEM. Strikingly, the results showed that, whereas Prx1 WT lungs possessed a dense, solid elastic lamina, Prx1 null lungs displayed a thinner, patchy, discontinuous elastic lamina ( Fig. 1D ). To examine whether Prx1 directly affects the expression of these elastic ECM components, a full-length Prx1 cDNA-containing plasmid 30 was transiently transfected to 10T1/2 cells, a mesenchymal precursor cell line, and mRNA expression of these elastic ECM components was examined ( Fig. S1B-S1D ). Overexpression of the Prx1 gene ( Fig. S1B ) was followed by increased mRNA expression of tropoelastin ( Fig. S1C ; 2.968e6 ± 1.175e7 vs. 0.9973e7 ± 0.9e9) and Fbn1 ( Fig. S1D; 4 .961e4 ± 1.566e4 vs. 3.234e4 ± 0.150e4). In support of the above results, because the promoter regions of tropoelastin, Fbn1, and Fbn2 contain conservative Prx1-binding sequences, it is plausible that Prx1 directly binds to and regulates expression of these elastic ECM components.
Prx1 null lungs have defective vascular SMC differentiation
Since elastic ECM properties are essential for vascular SMC differentiation, 13, 14 we examined vascular SMC differentiation in Prx1 WT and Prx1 null lungs. Immunostaining of E15.5 and D0 lungs for α-SMA ( Fig. 2A, left; Fig. 2B ), γ-SMA ( Fig. 2A, middle) , and SM22α ( Fig. 2A, right) showed that SMCs within developing pulmonary vessels in Prx1 WT mice strongly expressed SMC markers (i.e., α-SMA, γ-SMA, and SM22α) and possessed a spindle-shaped morphology ( Fig. 2B ). In contrast, Prx1 null lungs expressed reduced levels of the SMC markers examined, and vascular wall cells appeared to possess a rounded, more primitive morphology ( Fig. 2B ). Furthermore, whole-mount immunostaining of E17.5 lungs with α-SMA clearly showed that 3-D development and differentiation of vascular SMCs was deficient in Prx1 null lungs compared with Prx1 WT lungs (Fig. 2C) . Consistent with the staining results, mRNA expression of α-SMA ( Fig. 2D ), SM22α (Fig. 2E ), and SMMHC ( Fig. 2F ) in Prx1 null lungs at this stage was significantly reduced compared with that in Prx1 WT lungs.
TGF-β signaling was downregulated in Prx1 null lungs
It was recently reported that ECM properties regulate the activity of TGF-β1 signaling, 19, 38 a potent inducer of vascular SMC differentiation. 8 Since Prx1-deficient mice demonstrated compromised ECM composition and deficient SMC differentiation, we examined TGF-β expression and signaling in Prx1 WT and Prx1 null lungs. Im- munohistochemistry on Prx1 WT and Prx1 null lung sections showed that both TGF-β1 and TGF-β2 strongly localize in and around the developing vessels in Prx1 WT lungs (Fig. 3A) , while in Prx1 null lungs both TGF-β1 and TGF-β2 are less expressed in the vicinity of vessels and appear frequently in parenchyma (Fig. 3A) . Interestingly, Western blotting and real-time PCR showed that total TGF-β1 expression in Prx1 WT and Prx1 null lungs was not significantly different at the protein and mRNA levels (Fig. 3B, 3C) ; however, phosphorylation of the TGF-β downstream signaling mediator Smad2 (Fig. 3D) and expression of the TGF-β-regulated protein plasminogen activator inhibitor type 1 (PAI-1; Fig. 3E ) were reduced in Prx1 null lungs compared with Prx1 WT lungs. These results indicate that Prx1 regulates TGF-β signaling, potentially because of its effects on lung matrix.
Prx1 controls the biomechanical properties of lung ECM
Since our data suggested a strong link between Prx1-dependent formation of elastic ECM and development of the lung vascula-ture, we further examined the ECM in Prx1 WT and Prx1 null lungs.
To characterize the ECM derived from Prx1 WT and Prx1 null lungs and to elucidate the role played by Prx1-dependent ECM properties in vascular SMC differentiation, we developed a system to decellularize fetal mouse lungs in which proper removal of cells from the tissue leaves behind a complex ECM and associated proteins, including growth factors. 39 Decellularized scaffolds have proven to be useful tools for studying cell signaling in an appropriate 3-D ECM environment as well as for tissue engineering studies designed for clinical applications. 40 Therefore, we used the decellularized scaffolds to examine the architectural, biomechanical, and biochemical properties of the ECM in Prx1 null lungs. First, we used hematoxylin nuclear staining on intact and decellularized frozen lung sections and confirmed that cells were removed successfully by the decellularization process (Fig. 4A ). Next, we immunostained intact and decellularized Prx1 WT lungs to determine whether decellularized scaffolds retain ECM components. The results showed that the decellularized scaffolds clearly retained Fbn2, tropoelastin, and TGF-β1 ( Fig. 4B) as well as basement component laminin (Fig. S2 ). We also examined the stiffness of intact and decellularized Prx1 WT lung scaffolds (Fig. 4C ). As other groups have observed, 41 decellularization leads to reduced stiffness (1,486 ± 1,029 Pa) compared with that in intact lungs (2,577 ± 670 Pa), likely due to loss of cellular tension. These results confirmed that cells were successfully removed while ECM components were retained.
We used these lung scaffolds to characterize Prx1-dependent properties of the lung ECM. Consistent with the staining of intact tissue (Fig. 1) , immunostaining showed that Fbn2 and tropoelastin were decreased in Prx1 null scaffolds compared with Prx1 WT lung scaffolds (Fig. 5A ). Furthermore, the localization of TGF-β1 in the ECM was diffuse in Prx1 null scaffolds, whereas it was strongly deposited in the vicinity of the airway and vessels in Prx1 WT lung scaffolds (Fig. 5A ). We also examined the stiffness of E17.5 lung scaffolds by indentation testing with a 550-μm-diameter probe (Fig. 5B ). Prx1 null lung scaffolds (398 ± 209 Pa) were significantly softer than Prx1 WT lung scaffolds (1486 ± 1029 Pa; Fig. 5B ). We then used SEM and TEM studies to examine the ultrastructural architecture of the ECM. SEM images showed that Prx1 WT scaffolds possessed a well-assembled ECM, bearing a variety of sizes of interlinked fibrillar networks (Fig. 5C, left) . In contrast, Prx1 null lung scaffolds possessed a less fibrillar and more disorganized structure (Fig. 5C, right) . TEM images were consistent with SEM level analysis, showing that E17.5 Prx1 null lung scaffolds possessed a less developed fibrillar network (Fig. 5D , right) compared with that of the Prx1 WT scaffolds (Fig. 5D, left) . Fiber sizes constructing lung ECM scaffolds were measured using XL20 ESEM imaging software (Philips) and ImageJ. We found that fiber sizes of Prx1 null ECM were significantly different from those of Prx1 WT ECM. Prx1 WT ECM fibrils (42.7 ± 30.5 nm) were on average of smaller diameter than Prx1 null ECM fibrils (69.8 ± 21.5 nm) but had a wider range of sizes ( Fig. S3 ), which is consistent with the ultrastructural observations (Fig. 5C, 5D ). These results clearly indicate that Prx1 controls ECM architecture and physical properties by regulating ECM composition.
ECM stiffness and TGF-β signaling tightly cooperate in vascular SMC differentiation in 2-D and 3-D synthetic substrates
To determine whether Prx1-dependent ECM stiffness regulates vascular SMC differentiation and whether TGF-β signaling is involved in this process, we first confirmed that 10T1/2 mesenchymal precursor cells differentiate into SMC-like cells in response to TGF-β1. 17, 42 An immunocytochemical study showed that 10T1/2 cells respond to the TGF-β1 stimulation and induce SMC differentiation markers, such as α-SMA, γ-SMA, SM22α, and SMMHC (Fig. 6A ), while cells not stimulated or cotreated with TGF-β and LY364947, an inhibitor of the TGF-β type I receptor, exhibited low-level expression ( Fig. 6A) . Activation of TGF-β signaling was confirmed by demonstrating increased expression of PAI-1, a well-recognized target of the canonical TGF-β pathway (Fig. 6B, bottom) . Conversely, cotreatment of 10T1/2 cells with TGF-β1 and LY364947 resulted in PAI-1 expression at basal levels (Fig. 6B, bottom) . In parallel, mRNA expression levels of α-SMA and γ-SMA were significantly increased in response to TGF-β stimulation but remained at basal levels with inclusion of the inhibitor (Fig. 6B, top, middle) . Western immunoblotting (Fig. 6C) for αand γ-SMA together with phosphorylated Smad2 showed the same response at the protein level as at the mRNA level. These studies confirm that 10T1/2 cells have the capacity to adopt a SMC-like phenotype in response to TGF-β signaling via the canonical pathway.
We used 10T1/2 cells cultured on stiffness-controlled PAA gels in 2-D culture (Fig. 7A) to determine whether Prx1-dependent biophysical properties of the ECM are critical factors in controlling mesenchymal cell differentiation and whether Prx1-dependent ECM stiffness alone is sufficient or whether TGF-β signaling needs to be involved in this process. 32, 38 By adjusting the concentration of bis-acrylamide within the gels, the bulk physical properties of these substrates were designed to match the stiffness of either Prx1 WT (i.e., 1,500-Pa) or Prx1 null (i.e., 500-Pa) lung scaffolds. Expression of the SMC differentiation markers α-SMA, SM22α, and SMMHC was examined following culture of 10T1/2 cells on these PAA gels. Fluorescence microscopy images showed that in the absence of TGF-β1, . 10T1/2 cell differentiation to a smooth muscle phenotype is transforming growth factor (TGF)-β dependent. A, Immunostaining for α-smooth muscle actin (SMA), γ-SMA, SM22α, and smooth muscle myosin heavy chain (SMMHC; all positive reactions are green) in 10T1/2 cells, with or without TGF-β1 treatment, in the presence or absence of a TGF-β type I receptor (TGF-βRI) inhibitor (LY364947). Scale bar = 10 μm. B, αand γ-SMA messenger RNA expression in 10T1/2 cells after stimulation with TGF-β1, with or without LY364947. Plasminogen activator inhibitor type 1 (PAI-1) was used as a positive control for canonical TGF-β signaling activation. Signals were normalized to GAPDH. C, Western immunoblotting for αand γ-SMA expression in 10T1/2 cells after stimulation with TGF-β1, with or without a TGF-βRI inhibitor (SB431542). Phosphorylation of Smad2 (P-Smad2) was examined as a marker of canonical TGF-β signaling. GAPDH was used as a loading control. 10T1/2 cells cultured on the stiffer substrate developed a relatively elongated morphology and more marker expression ( Fig. 7B) ; with TGF-β1 treatment, characteristics of the SMC-like phenotype, such as cell elongation and SMC marker expression, were further increased (Fig. 7B, top vs. bottom) . In contrast, 10T1/2 cells cultivated on the softer Prx1 null -stiffness substrate retained mesenchymal-like morphology and expressed low levels of SMC markers with or without TGF-β1 stimulation (Fig. 7B ) compared with cells cultured on stiffer Prx1 WT -stiffness substrates. To quantify the morphological change of cell shape, the aspect ratio was measured (Fig. 7C ). Supporting the cell morphological observation of immunocytochemistry, 10T1/2 cells cultured on stiffer substrates had a higher aspect ratio (more elongated SMC-like morphology), and the effect of TGF-β on the aspect ratio was enhanced by a stiffer substrate. Realtime PCR for SMC differentiation markers (α-SMA, SM22α, and SMMHC) demonstrated that mRNA expression of the SMC differentiation markers was induced by stiffer substrates and enhanced by TGF-β signaling (Fig. 7D-7F ), which is parallel to the results of immunostaining. We also noted that among the SMC differentiation markers we examined, expression of α-SMA, an initial SMC differentiation marker, showed the most significant differences between the culture settings (Fig. 7B, 7D ) compared with the expression of SM22α (Fig. 7B, 7E) and SMMHC (Fig. 7B, 7F ), which are more mature SMC markers and are significantly induced only in the cells seeded on the 1,500-Pa substrates with TGF-β stimulation. This indicates that the 24-hour biophysical and biochemical stimulation leads to an initial stage of SMC differentiation from embryonic precursor cells but is not sufficient to achieve full differentiation. Taken together, these results indicate that ECM stiffness is a key determinant in controlling 10T1/2 cell differentiation to SMCs in conjunction with TGF-β stimulation. Our results also indicate that Prx1-dependent ECM stiffness alone is not sufficient to support mesenchymal cells to differentiate to the smooth muscle phenotype and requires coordination with TGF-β signaling. For this event, Prx1 likely promotes SMC differentiation via its effect on both the biophysical and the biochemical properties of the developing lung ECM.
To further examine the effect of ECM stiffness on cell differentiation under more physiological conditions, we cultured 10T1/2 cells within chemically engineered 3-D substrates of different stiffness. Electrospun, MeHA gels were coated with type 1 collagen before being seeded with cells. 35 The stiffness of these synthetic scaffolds was measured by AFM after the scaffolds were rehydrated to determine the physiological stiffness. We used MeHA gels with stiffness of ≃1,000 Pa to represent a soft ECM and of ∼3,000-5,000 Pa to represent a stiffer ECM for cell culture. 34 3-D projections of confocal microscope images outlined by cellular F-actin staining showed that on soft 3-D scaffolds 10T1/2 cells sporadically aggregated and failed to differentiate or assemble functional vascular SMC-like networks (Fig. 7G ). Within the stiffer 3-D microenvironment, however, cells grew into the MeHA substrate and demonstrated prominent network formation with elongated cell morphologies (Fig. 7G) , consistent with functional SMC differentiation. Although the synthetic scaffold stiffness is not identical to the Prx1 WT and Prx1 null lung scaffold stiffness because of technical limitations, these results suggest that 3-D stiffness cues have a stronger effect on 10T1/2 cell to SMC functional differentiation than 2-D cues.
Prx1-dependent ECM regulates SMC differentiation in a TGF-β-dependent manner
Finally, we asked whether acellular Prx1 WT and Prx1 null lung scaffolds differentially support SMC differentiation. We seeded and cultured 10T1/2 cells in decellularized lung scaffolds derived from Prx1 WT and Prx1 null mice. After 5 days in culture, cells had clearly migrated into both Prx1 WT and Prx1 null scaffolds, yet their organization and morphology greatly differed: recolonization of vascular structures was clearly evident for 10T1/2 cells in Prx1 WT lung scaffolds (Fig. 8A, left) compared with the Prx1 null scaffolds, within which cells appeared to be randomly distributed (Fig. 8A, right) . Furthermore, expression of α-SMA of seeded cells in Prx1 WT scaffolds was greater than that in Prx1 null scaffolds (Fig. 8A, 8B ). SEM images for ultrafine structures support the immunostaining results that 10T1/2 cells on Prx1 WT scaffolds possess a more elongated SMC-like phenotype compared with those cultivated on Prx1 null scaffolds (Fig. 8E) . Consistent with the idea that Prx1dependent ECM properties play a major role in mesenchymal cell to SMC differentiation, we tested whether 10T1/2 cell differentiation within Prx1 WT scaffolds is simply dependent on the mechanical properties of the ECM or is also dependent on the biochemical properties of the ECM, TGF-β. We pretreated Prx1 WT scaffolds with a function-blocking anti-TGF-β1 antibody and then seeded 10T1/2 cells. Whereas IgY-treated controls adopted the expected elongated and differentiated phenotype, including expression of α-SMA (Fig. 8C ), cultures treated with anti-TGF-β1 IgY failed to colonize scaffolds appropriately, adopted a nondifferentiated morphology, and expressed reduced levels of α-SMA (Fig. 8C, 8D ). Collectively, these results strongly suggest that Prx1 plays a critical role in lung vascular SMC differentiation during embryonic development by coordinating the biophysical and biochemical properties of the ECM.
DISCUSSION
Vascular morphogenesis is critical for the development and regeneration of functional lung tissues. In the past, research on developmental biomechanics was focused on developing theoretical models and using in vitro experimental approaches for model validation. However, recently it has been recognized that morphogenesis occurs through more dynamic interactions between cells and through biochemical and biomechanical microenvironmental cues that are not well understood from individual cell culture models. In this study, we demonstrated that the homeobox transcription factor Prx1 plays an essential role in embryonic lung vascular SMC differentiation by regulating the biophysical and biochemical properties of the ECM (Fig. 9 ).
In this study, the results comparing Prx1 WT and Prx1 null mice demonstrated that Prx1 regulates expression of elastic ECM components, such as tropoelastin, Fbn1, and Fbn2, in the lungs. In Prx1 null lungs, the expression of these elastic ECM components is downregulated around the developing vessels, and vascular SMC differentiation is compromised. Elastic ECM is a major component of the lungs, consisting of elastin and associated microfibrils, such as fibrillins. 11, 12, [43] [44] [45] [46] [47] In animal models, defects of a single gene of these elastic ECM components have been shown to contribute to various vascular diseases. For example, mutations in tropoelastin cause occlusive arterial disease in humans, 15, 48 and elastin-deficient mice die shortly after birth due to aberrant subendothelial cell proliferation and reorganization of the SMC layer. 13, 49 In addition, elastin-associated microfibril proteins in fibrillin 50,51 and fibulin 45, 52, 53 families also regulate vascular SMC differentiation. However, the upstream regulator orchestrating these elastic ECMs during embryonic development is unknown. While previous studies have shown that Prx1 regulates vascular SMC differentiation in the adult by direct transcriptional regulation of α-SMA transactivation 54, 55 acting as a cofactor for serum response factor, 55,56 this mechanism has not been found to regulate initial SMC marker gene expression in early embry- onic stages. 57 Therefore, the differences in elastic ECM composition between Prx1 WT and Prx1 null lungs suggest a new indirect role for the transcription factor Prx1 in embryonic lung vascular morphogenesis by organizing elastic ECM during embryonic development.
Decellularized lung ECM scaffolds enabled us to demonstrate that differences in elastic ECM composition between Prx1 WT and Prx1 null strongly affect the architecture and ultrastructural fiber formation of ECM in embryonic lungs. For instance, SEM images and fiber measurement showed that the fiber diameter of Prx1 WT has wide variations, while Prx1 null has a more uniform intermediate size, which supports previous findings that the insufficiency of elastin and fibrillins prevents the proper maturation of fibers. 11, 58 The variation in the fiber size of the ECM in Prx1 WT indicates more maturation of ECM fibers to construct the proper microenvironment for vascular development, while Prx1 null ECM with a uniform size of fibers results in a lack of a specific microstructure to support functional vascular development. Therefore, the fiber size of the ECM could be a key indicator of the biophysical properties of the ECM. In this study, this structural maturation in the ECM by Prx1 was reflected in the biophysical property of stiffness, resulting in a softer Prx1 null ECM (398 ± 209 Pa) and a more rigid Prx1 WT ECM (1,486 ± 1,029 Pa). Similar to the recent studies that show that the stiffness of the ECM has a profound influence on stem/progenitor cell fate determination and differentiation in adult tissues in both normal and pathological settings, [2] [3] [4] 59, 60 our results suggest that embryonic lung vascular morphogenesis is regulated by ECM stiffness and that Prx1 plays a key role in this regulation, a notion supported by the cell culture results using stiffnesscontrolled 2-D and 3-D synthetic substrates.
In addition to biophysical properties, biochemical properties, such as growth factor stimulation of the ECM, play an essential role in regulating cell growth. During embryonic lung development, it has been well established that temporal spatial gradients of growth factors surrounding the developing airway and vessels are essential for lung morphogenesis. [6] [7] [8] 10, 61 However, many studies using transgenic animal models and/or conventional cell culture systems could not elucidate the dynamics of the microenvironment in tissue and organ development. In this study, our results show that while the expression of TGF-β was not significantly different between Prx1 WT and Prx1 null lungs, downstream canonical signaling activity was decreased in Prx1 null lungs. Furthermore, the immunohistochemistry of intact and ECM scaffold lungs showed that the localization of TGF-β is diffusely spread out in Prx1 null lungs, while the localization is condensed around the growing vessels and airways in Prx1 WT lungs. Since an elastic matrix has been considered to play an essential role in vascular cell differentiation and functional maturation by acting as a reservoir for multiple growth factors 40 and since fibrillins tether TGF-β, 8, 62 which controls its bioavailability, these differences in TGF-β localization are regulated by the Prx1-dependent elastic ECM components. Supported by previous studies using fibrillin-deficient mice, which present hypoplasia of airway and vascular systems due to compromised TGF-β tempospatial availability during development, [63] [64] [65] our results suggest that Prx1 maintains a precise bioavailability of TGF-β during lung development by regulating elastic ECM properties.
We further examined the interaction between TGF-β activation and stiffness of Prx1-dependent ECM in lung development since a previous study showed that ECM stiffness can regulate activation of TGF-β and induce cell differentiation. 19 Since our results showed that canonical TGF-β signaling was downregulated in Prx1 null lungs accompanied by low stiffness in the ECM, stiffness of Prx1-dependent ECM plays a role in regulating local TGFβ activation and subsequent SMC differentiation. In addition, the results using stiffness-controlled 2-D and 3-D culture substrates and decellularized lung scaffolds demonstrated that Prx1-dependent ECM stiffness has a substantial effect on SMC differentiation even without TGF-β stimulation and that TGF-β alone could not fully rescue SMC differentiation on soft Prx1 null scaffolds. On the other hand, our results also showed that matrix stiffness alone is not sufficient to control vascular SMC differentiation, while blocking TGF-β dramatically reduced SMC differentiation and functional maturation. Since stiffness of the ECM also regulates noncanonical TGF-β activation in different settings and regulates cell differentiation and fate determinations, 60, 66 it is plausible that Prx1-dependent ECM also regulates TGF-β signaling via a noncanonical pathway; this requires future investigation.
Our results strongly suggest that Prx1 regulates a unique pathway in lung vascular smooth muscle development by coordinating biophysical and biochemical properties of the ECM during embryonic development. In addition to TGF-β, there is also a possibility that Prx1-dependent ECM coordinates other growth factor pathways in lung vascular morphogenesis. For example, Wnt, a key regulator of lung morphogenesis, responds to ECM stiffness; 67 we have reported that Wnt7b signaling is regulated by tenascin C, which is downstream of Prx1. 68 In addition, the roles played by ECM characteristics other than stiffness, such as composition and architecture, in SMC differentiation require further investigation. It is plausible that Prx1 maintains temporal and spatial stiffness and growth factor bioavailability by precisely controlling the ECM properties around the developing embryonic lung tissue; this requires future investigation. Once technical limitations for regional stiffness measurements can be overcome, we will have the ability to generate more precise information about the temporal and spatial coordination of biophysical and biochemical signals controlled by Prx1. These future studies will enable better understanding of the regulation of embryonic lung cell differentiation, tissue development, and functional maturation controlled by ECM properties, which would create a fundamental understanding of ontogeny of the cardiovascular system and the development of cell-ECM-based therapies.
In conclusion, we report here that Prx1 indirectly regulates lung vascular SMC differentiation by controlling elastic ECM properties. By focusing on Prx1, this work provides essential information on the role played by the transcription factor in association with the control of ECM properties in specifying the final shape and architecture of lung vascular morphogenesis. We believe that our findings contribute to advancing knowledge of the biophysical and biochemical processes that occur during normal and abnormal embryonic lung vascular development and have implications for the design of regenerative therapies by combining stem/progenitor cells and ECM applications.
